Searle & CO. increased its holdings in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX – Free Report) by 684.1% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 86,250 shares of the biotechnology company’s stock after acquiring an additional 75,250 shares during the quarter. Searle & CO.’s holdings in Heron Therapeutics were worth $172,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also bought and sold shares of HRTX. nVerses Capital LLC bought a new stake in shares of Heron Therapeutics in the second quarter valued at approximately $27,000. Headlands Technologies LLC acquired a new position in Heron Therapeutics in the 1st quarter valued at $30,000. Susquehanna Fundamental Investments LLC bought a new stake in shares of Heron Therapeutics during the 1st quarter valued at $32,000. HB Wealth Management LLC acquired a new stake in shares of Heron Therapeutics during the 2nd quarter worth $35,000. Finally, B. Riley Wealth Advisors Inc. bought a new position in shares of Heron Therapeutics in the second quarter worth $41,000. Institutional investors and hedge funds own 80.01% of the company’s stock.
Heron Therapeutics Price Performance
HRTX traded up $0.03 during trading on Wednesday, hitting $1.81. 519,303 shares of the stock traded hands, compared to its average volume of 2,440,008. The business has a 50 day moving average price of $1.90 and a 200 day moving average price of $2.64. Heron Therapeutics, Inc. has a twelve month low of $0.50 and a twelve month high of $3.93. The company has a market cap of $271.93 million, a price-to-earnings ratio of -2.92 and a beta of 1.80.
Wall Street Analysts Forecast Growth
Separately, Needham & Company LLC reaffirmed a “buy” rating and set a $5.00 price objective on shares of Heron Therapeutics in a research report on Wednesday, September 25th.
Get Our Latest Stock Report on Heron Therapeutics
Heron Therapeutics Company Profile
Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
Featured Stories
- Five stocks we like better than Heron Therapeutics
- Conference Calls and Individual Investors
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- Industrial Products Stocks Investing
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- What is a Stock Market Index and How Do You Use Them?
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Want to see what other hedge funds are holding HRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heron Therapeutics, Inc. (NASDAQ:HRTX – Free Report).
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.